This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
4 Buy-Ranked Large Cap Pharma Stocks to Add to Your Portfolio
by Arpita Dutt
The Zacks-categorized Large Cap Pharmaceuticals industry is among the top 21% of the 256 Zacks-ranked industries -- here is a look at 4 top-ranked stocks from this sector.
Nektar (NKTR) Stock Rallied Almost 50% This Year: Here's Why
by Zacks Equity Research
Shares of Nektar Therapeutics (NKTR) are up almost 48% this year so far, outperforming the Zacks classified Medical-Drugs industry's registered increase of 3.6% during this period.
Here's Why Clovis (CLVS) Stock is Up Almost 350% in One Year
by Zacks Equity Research
Shares of Clovis Oncology, Inc. (CLVS) continue to witness an upside. The uptrend started in the third quarter of 2016.
Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused
by Arpita Dutt
Merck (MRK) paused patient enrolment in a couple of studies being conducted with its anti-PD-1 therapy, Keytruda.
Pfizer (PFE) Buys Exclusive EU Rights to Anti-Fungal Drug
by Zacks Equity Research
Pfizer, Inc. (PFE) announced a deal to buy exclusive EU commercialization rights to an anti-fungal treatment, Cresemba from Swiss pharma company, Basilea Pharmaceutica Ltd.
J&J's Invokana Lowers Heart Issues, Raises Amputation Risk
by Zacks Equity Research
Johnson & Johnson (JNJ) announced data from a large CANVAS outcomes program, which demonstrated that its type II diabetes drug Invokana (canagliflozin) was successful in reducing the risks of heart attacks and strokes.
AstraZeneca (AZN) Divests Migraine Drug Rights Beyond Japan
by Zacks Equity Research
AstraZeneca PLC (AZN) has inked a deal to sell the global rights of migraine treatment drug Zomig (zolmitriptan) outside Japan to Grunenthal, a German pharmaceutical company.
Intellipharmaceutics Announces Launch of Generic Seroquel XR
by Zacks Equity Research
Intellipharmaceutics International Inc. (IPCI) announced the launch of a generic version of schizophrenia drug Seroquel XR by its marketing and distribution partner in the U.S, Mallinckrodt Public Limited Company
Incyte Provides Updated Data on Cancer Combination Therapies
by Zacks Equity Research
Incyte along with partner Bristol-Myers Squibb announced updated data from phase I/II study, ECHO-204, evaluating epacadostat in combination with Opdivo for the treatment of squamous cell carcinoma of the head and neck and melanoma.
Incyte Announces Data on Enzyme Inhibitor with Keytruda
by Zacks Equity Research
Incyte Corporation (INCY) and Merck & Co. (MRK) announced an updated data from the advanced non-small cell lung cancer patient cohort of the ongoing phase I/II ECHO-202 study.
Big Pharma Diabetes Drugs Not So Sweet. What's in Store?
by Zacks Equity Research
Aales of diabetes drugs from most large pharma companies slipped in the first quarter.
Are Nektar's (NKTR) Key Drugs Set to Drive Growth in 2017?
by Zacks Equity Research
On May 29, 2017, we issued an updated report on Nektar Therapeutics (NKTR).
Sanofi (SNY) Stock Continues to Gain on Key Drug Approvals
by Zacks Equity Research
After declining in 2016, share price of French pharma giant Sanofi (SNY) has picked up in 2017.
AstraZeneca's Bydureon Fails to Reduce Cardiovascular Risk
by Zacks Equity Research
AstraZeneca plc (AZN) announced top-line results from the EXSCEL study evaluating the cardiovascular (CV) safety profile of its type II diabetes drug Bydureon.
The Zacks Analyst Blog Highlights: Oracle, Chubb, AstraZeneca, Estee Lauder and Aflac
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Oracle, Chubb, AstraZeneca, Estee Lauder and Aflac
AstraZeneca Sells Marketing Rights to Seloken in Europe
by Zacks Equity Research
AstraZeneca plc (AZN) announced that it has signed an agreement with Recordati S.p.A, granting commercial rights to Seloken/Seloken ZOK and associated Logimax fixed-dose combination to the latter in European markets.
AstraZeneca PLC (AZN): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
AstraZeneca (AZN) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.
Astrazeneca (AZN) Gets Positive CHMP Opinion for Brodalumab
by Zacks Equity Research
Astrazeneca PLC (AZN) and its partner LEO Pharma received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Clovis' (CLVS) PARP Inhibtor Shows Promise, Risks Remain
by Zacks Equity Research
On May 19, we issued an updated research report on Boulder, CO based Clovis Oncology, Inc. (CLVS).
Endocyte (ECYT) Focused on Two Lead Pipeline Candidates
by Zacks Equity Research
We issued an updated report on Endocyte, Inc. (ECYT) on May 17.
AstraZeneca Imfinzi Positive in Phase III Lung Cancer Study
by Zacks Equity Research
AstraZeneca PLC (AZN) recently announced positive data from a phase III PACIFIC study evaluating its oncology candidate, Imfinzi (durvalumab).
AstraZeneca (AZN) Shows Strength: Stock Moves 9.2% Higher
by Zacks Equity Research
AstraZeneca PLC (AZN) shares rose above 9% in the last trading session.
What's in Store for Merck KGaA (MKGAF) in Q1 Earnings?
by Zacks Equity Research
Merck KGaA (MKGAF) is scheduled to report first-quarter 2017 earnings results on May 18.
Pharma Stock Roundup: Mylan, Teva Q1 Earnings, Roche Drug Misses in Pivotal Study
by Arpita Dutt
While companies like Mylan (MYL), Allergan and Teva reported Q1 results this week, several companies provided updates on their cancer drugs.
Nektar Therapeutics (NKTR) Loss Wider Than Expected in Q1
by Zacks Equity Research
Nektar Therapeutics (NKTR) reported first-quarter 2017 loss of 42 cents per share, wider than the Zacks Consensus Estimate of a loss of 40 cents.